MAR 03, 2021 7:49 AM PST

Keeping HIV Latent

WRITTEN BY: Nouran Amin

When (HIV) human immunodeficiency virus infects cells, it can go to sleep as opposed to make viral copies of itself—the process is known as latency. However, keeping HIV+ cells latent so it does not cause harm to the host remains a challenge.

900

"The current drug treatments block healthy cells from becoming infected by the virus," said Yiyang Lu, a PhD student in the Dar lab at the University of Illinois Urbana-Champaign. "The latent reservoir poses a bigger problem because it can start producing the virus at any time. Consequently, patients have to remain on antiretroviral therapy all their lives to prevent a viral rebound."

Now, researchers have found a way to use compounds to keep the suppression of HIV+ cells in an ongoing dormant state. The findings were published in the Proceedings of the National Academy of Sciences (PNAS).

"Commercial drug screens usually look at mean gene expression. Instead, we used a drug screen that looks at fluctuations in gene expression. Our screen allowed us to therefore find more compounds that could have been overlooked," Lu said.

Learn more about HIV:

"We implemented a time-series drug screening approach that are less commonly used in other labs," said Roy Dar, an assistant professor of bioengineering at Illinois and faculty member of the Carl R. Woese Institute for Genomic Biology.

"We want to test if these drugs have off-target effects in terms of how many other genes they affect in the host cells," Dar said. "We also want to test these drugs in patient samples to see whether these drugs suppress HIV in them."

Source: Science Daily

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 15, 2022
Drug Discovery & Development
First Drug for Sleep Apnea Shows Promise in Patients
APR 15, 2022
First Drug for Sleep Apnea Shows Promise in Patients
A new drug for sleep apnea could reduce breathing pauses during sleep by over 20 per hour. The corresponding study was p ...
MAY 15, 2022
Drug Discovery & Development
Implanted Insulin-producing Cells for Diabetes Treatment
MAY 15, 2022
Implanted Insulin-producing Cells for Diabetes Treatment
Type 1 diabetes, which affects about 9 to 10 million people globally, occurs when the immune system incorrectly identifi ...
MAY 20, 2022
Drug Discovery & Development
Drug Shows Promise in treating Spinal Cord Injury
MAY 20, 2022
Drug Shows Promise in treating Spinal Cord Injury
A drug developed by AstraZeneca preserves 80% of nerve function following spinal cord compression injury. The correspond ...
JUN 02, 2022
Coronavirus
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
JUN 02, 2022
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
It has been clear for some time that loneliness and social isolation can lead to increased risks for adverse h ...
JUN 04, 2022
Drug Discovery & Development
Antibiotics Reduce Motivation to Exercise in Mice
JUN 04, 2022
Antibiotics Reduce Motivation to Exercise in Mice
Antibiotics may decrease athletes' motivation and endurance via effects on the microbiome. The corresponding study w ...
JUN 11, 2022
Drug Discovery & Development
Inhaled Aerosol Vaccines More Effective than Nasal Sprays
JUN 11, 2022
Inhaled Aerosol Vaccines More Effective than Nasal Sprays
Inhaled aerosol vaccines provide more protection than nasal sprays and evoke a stronger immune response. The correspondi ...
Loading Comments...